{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Beauchamp E"],"funding":["Medical Research Council","Alberta Cancer Foundation","Alberta Innovates Translational Health Chair"],"pagination":["5348"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7582192"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["11(1)"],"pubmed_abstract":["Myristoylation, the N-terminal modification of proteins with the fatty acid myristate, is critical for membrane targeting and cell signaling. Because cancer cells often have increased N-myristoyltransferase (NMT) expression, NMTs were proposed as anti-cancer targets. To systematically investigate this, we performed robotic cancer cell line screens and discovered a marked sensitivity of hematological cancer cell lines, including B-cell lymphomas, to the potent pan-NMT inhibitor PCLX-001. PCLX-001 treatment impacts the global myristoylation of lymphoma cell proteins and inhibits early B-cell receptor (BCR) signaling events critical for survival. In addition to abrogating myristoylation of Src family kinases, PCLX-001 also promotes their degradation and, unexpectedly, that of numerous non-myr"],"journal":["Nature communications"],"pubmed_title":["Targeting N-myristoylation for therapy of B-cell lymphomas."],"pmcid":["PMC7582192"],"funding_grant_id":["26362","26927","MC_G0900864","26380"],"pubmed_authors":["Perinpanayagam MA","Gamma JM","Gray DW","Dong WF","Tan SY","Yap MC","Raju A","Postovit LM","Wyatt PG","Lakshmanan M","Iyer A","Mackey JR","Tergaonkar V","Vincent KM","Lim ST","Read KD","Berthiaume LG","Beauchamp E"],"additional_accession":[]},"is_claimable":false,"name":"Targeting N-myristoylation for therapy of B-cell lymphomas.","description":"Myristoylation, the N-terminal modification of proteins with the fatty acid myristate, is critical for membrane targeting and cell signaling. Because cancer cells often have increased N-myristoyltransferase (NMT) expression, NMTs were proposed as anti-cancer targets. To systematically investigate this, we performed robotic cancer cell line screens and discovered a marked sensitivity of hematological cancer cell lines, including B-cell lymphomas, to the potent pan-NMT inhibitor PCLX-001. PCLX-001 treatment impacts the global myristoylation of lymphoma cell proteins and inhibits early B-cell receptor (BCR) signaling events critical for survival. In addition to abrogating myristoylation of Src family kinases, PCLX-001 also promotes their degradation and, unexpectedly, that of numerous non-myr","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Oct","modification":"2026-05-07T15:12:41.429Z","creation":"2025-05-29T20:01:28.58Z"},"accession":"S-EPMC7582192","cross_references":{"pubmed":["33093447"],"doi":["10.1038/s41467-020-18998-1"]}}